|
|
Article: Biogen Idec Announces Multiple Sclerosis Franchise and Pipeline Presentations at the 60th Annual Meeting of the American Academy of Neurology.
- Article from:
- Business Wire
- Article date:
- April 15, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CHICAGO -- Biogen Idec (NASDAQ: BIIB) today announced that 17 company-sponsored plenary sessions, platform presentations, and poster presentations will be presented during the 60th Annual Meeting of the American Academy of Neurology. These presentations will cover four compounds that are marketed or currently in development by Biogen Idec and its partners for the treatment of multiple sclerosis (MS). This includes two approved therapies for MS; TYSABRI([R]) (natalizumab) and AVONEX([R]) (Interferon beta-1a); and two additional agents in development; BG-12 (dimethyl fumarate) and daclizumab.
"The presentations and posters at AAN show Biogen Idec's broad commitment ...
Related newspaper, magazine, and journal articles:
|
|
Article: Tysabri: clinical trials restart.(treatment for multiple ...
Chemistry and Industry;
March 6, 2006 ;
700+ words
... ... has lifted the ban on clinical trials of Tysabri as a monotherapy for multiple sclerosis (MS). Tysabri (natalizumab), a monoclonal antibody developed by Biogen Idec and Elan Pharmaceuticals, was approved in November 2004 and widely expected ...
|
|